Brazil's Anvisa spreads wings further with German health protection research collaboration
This article was originally published in Clinica
Executive Summary
Brazil’s healthcare products regulatory agency (Anvisa) and Germany’s federal institute for risk assessment (BfR) have agreed to work together in the field of risk assessment related to health protection. The two bodies signed a research collaboration and information-sharing agreement on 24 May, in a move that reflects the growing international reach and influence of Anvisa’s work. The BfR’s remit is to identify and assess existing and new health risks posed by products, substances and foodstuffs; it reports to Germany’s food, agriculture and consumer protection ministry (BMELV), but provides scientific advice to the relevant federal ministries.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.